This site is intended for Healthcare professionals only.

Lupin gets USFDA nod for Asthma drug


Lupin gets USFDA nod for Asthma drug

New Delhi: Drug major Lupin Tuesday said it has received approval from the US health regulator to market Budesonide Inhalation Suspension single-dose ampules, used for treating Asthma. The product approved by the United States Food and Drug Administration (USFDA) is a generic version of AstraZeneca Pharmaceuticals LP’s Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL, Lupin said in a regulatory filing.

Quoting IQVIA MAT September data, Lupin said, the said Asthma drug had annual sales of around USD 474.5 million in the US.

 

Read Also: Lupin gets FDA approval for Doxercalciferol Injection



Source: PTI
0 comment(s) on Lupin gets USFDA nod for Asthma drug

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted